港股首宗18A反向并购，通过港交所聆讯

张通社12-06 18:03

张通社 zhangtongshe.com｜立足张江，面向上海，服务科创｜近日，据港交所文件，嘉和生物药业（开曼）控股有限公司（以下简称“嘉和生物”）通过港交所上市聆讯，距离完成并购上市仅一步之遥。ZHANG TONG SHE2024年9月13日，嘉和生物与亿腾医药集团有限公司（简称“亿腾医药”）订立合并协议。亿腾医药拟通过换股方式反向收购嘉和生物，这是港股18A（依据修订的《主板上市规则》第18A...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2589222238?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-06 18:03","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2589222238","market":"hk","top_or_hot":-1,"title":"港股首宗18A反向并购，通过港交所聆讯","media":"张通社","content":"<div>\n<p>张通社 zhangtongshe.com｜立足张江，面向上海，服务科创｜近日，据港交所文件，嘉和生物药业（开曼）控股有限公司（以下简称“嘉和生物”）通过港交所上市聆讯，距离完成并购上市仅一步之遥。ZHANG TONG SHE2024年9月13日，嘉和生物与亿腾医药集团有限公司（简称“亿腾医药”）订立合并协议。亿腾医药拟通过换股方式反向收购嘉和生物，这是港股18A（依据修订的《主板上市规则》第18A...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251206181216a727753e&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股首宗18A反向并购，通过港交所聆讯</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股首宗18A反向并购，通过港交所聆讯\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-06 18:03 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251206181216a727753e&s=b><strong>张通社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>张通社 zhangtongshe.com｜立足张江，面向上海，服务科创｜近日，据港交所文件，嘉和生物药业（开曼）控股有限公司（以下简称“嘉和生物”）通过港交所上市聆讯，距离完成并购上市仅一步之遥。ZHANG TONG SHE2024年9月13日，嘉和生物与亿腾医药集团有限公司（简称“亿腾医药”）订立合并协议。亿腾医药拟通过换股方式反向收购嘉和生物，这是港股18A（依据修订的《主板上市规则》第18A...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251206181216a727753e&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09939","symbol_name":"开拓药业-B","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251206181216a727753e&s=b","article_id":"2589222238","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251206181216a727753e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2589222238","pubTimestamp":1765015403,"columns":[{"name":"聆讯消息","id":19,"label_key":null}],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"张通社 zhangtongshe.com｜立足张江，面向上海，服务科创｜近日，据港交所文件，嘉和生物药业（开曼）控股有限公司通过港交所上市聆讯，距离完成并购上市仅一步之遥。亿腾医药拟通过换股方式反向收购嘉和生物，这是港股18A首例反向收购案。如今，这场港股18A首例反向收购交易迎来最新进展，以更新后的招股书材料向港交所进一步推进上市流程。亿腾医药此前曾四次递交H股发行上市申请，期间曾在2021年6月通过港交所聆讯，但彼时公司未启动招股。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"80388":"香港交易所-R","09939":"开拓药业-B","LU1282649141.HKD":"ALLIANZ ASIAN MULTI INCOME PLUS \"AMG\" (HKD) INC","LU0577902371.SGD":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"I\" (SGD) ACC","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","00388":"香港交易所","BK1131":"金融交易所和数据","LU0370786039.SGD":"Fidelity Greater China A-SGD","LU0096374516.USD":"CT (LUX) I ASIA EQUITY INCOME \"DU\" (USD) ACC","LU0594300419.USD":"富达中国消费基金A","LU1981816686.USD":"EASTSPRING INV ASIAN MULTI FACTOR EQUITY \"A\" (USD) ACC","LU0072462343.USD":"贝莱德亚洲巨龙基金","LU0650527681.SGD":"Fidelity China Consumer A-SGD","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU1481107354.HKD":"HSBC GIF HONG KONG EQUITY \"AD\" (HKD) INC","HKXCY":"香港交易所ADR","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","BK1161":"生物科技","BK1610":"ETF&股票定投概念","LU0594300179.USD":"FIDELITY CHINA CONSUMER \"A\" (USD) ACC","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU2257852520.SGD":"JPMorgan Funds - Asia Growth A (acc) SGD","LU0762541174.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED INCOME \"AM2\" (USD) INC","LU0791590937.USD":"ALLSPRING  EMERGING MARKTES EQUITY INCOME \"A\" (USD)","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU0648948544.HKD":"ALLIANZ ASIAN MULTI INCOME PLUS \"AM\" (HKD) INC","LU0384037296.USD":"ALLIANZ ASIAN MULTI INCOME PLUS \"AT\" (USD) ACC","LU0762542818.HKD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED INCOME \"AM\" (HKD) INC","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","06998":"嘉和生物-B","LU0197773160.USD":"HSBC GIF ASIA PACIF EX JAPAN EQ HD \"AC\" ACC","BK1574":"生物医药B类股","LU0169518387.USD":"JPM ASIA EQUITY \"A\" ACC","LU0106959298.USD":"UBS (LUX) EQUITY FUND - EMERGING MARKETS SUSTAINABLE LEADERS (USD) \"P\" (USD) ACC","LU0762540952.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED INCOME \"AC\" (USD) ACC","LU0197773673.USD":"HSBC GIF ASIA PACIF EX JAPAN EQ HD \"AS\" (USD) INC","LU1044875133.USD":"天利亚洲反向股票 AU Acc","BK1583":"高瓴概念","LU0955623706.USD":"SCHRODER ISF ASIAN DIVIDEND MAX \"A\" (USD) ACC","LU0651947912.USD":"BGF EMERGING MARKETS EQUITY INCOME \"A5G\" (USD) INC","LU0211977185.USD":"EASTSPRING INVESTMENTS GREATER CHINA EQUITY \"A\" ACC","LU1734074674.USD":"NINETY ONE GSF ASIA PACIFIC FRANCHISE \"A\"(USD) ACC","IE0003851619.USD":"BNY MELLON ASIAN EQUITY \"B\" (USD) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","BK1589":"北水核心资产","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC"},"translate_title":"The first 18A reverse merger and acquisition of Hong Kong stocks passed the hearing of the Hong Kong Stock Exchange","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"80388":0.6,"HEXmain":0.6,"09939":0.9,"HKXCY":0.6,"06998":0.71,"00388":0.9},"content_text":"张通社 zhangtongshe.com｜立足张江，面向上海，服务科创｜近日，据港交所文件，嘉和生物药业（开曼）控股有限公司（以下简称“嘉和生物”）通过港交所上市聆讯，距离完成并购上市仅一步之遥。ZHANG TONG SHE2024年9月13日，嘉和生物与亿腾医药集团有限公司（简称“亿腾医药”）订立合并协议。亿腾医药拟通过换股方式反向收购嘉和生物，这是港股18A（依据修订的《主板上市规则》第18A章上市的生物科技企业）首例反向收购案。如今，这场港股18A首例反向收购交易迎来最新进展，以更新后的招股书材料向港交所进一步推进上市流程。嘉和生物成立于2007年，2020年登陆港股市场，是国内第一批生物制药公司，专注于肿瘤及自身免疫药物的研发及商业化。亿腾医药成立于2001年，总部位于上海，是一家综合型的专业生物制药公司。公司通过向跨国医药公司收购品牌药物资产，并从全球生物制药公司授权引进创新专利药物的开发及商业化权利，已建立富有竞争力的原研药及创新药组合。亿腾医药已建立优质产品组合，包括五款主要产品，其中包括三款原研产品，即稳可信、希刻劳及亿瑞平，以及两款创新产品（即Vascepa及Mulpleta），这些主要产品已全部实现商业化。每款产品均针对大型或快速增长的治疗领域的医疗需求，包括抗感染、CVD及呼吸系统疾病。亿腾医药为其所有主要产品于中国的上市许可持有人。在营业记录期间，亿腾医药大部分收入来自销售原研产品。财务方面，招股书显示，2022年、2023年、2024年及2025年上半年，亿腾医药净利润分别为3.06亿元、3.08亿元、3.88亿元、1.15亿元。亿腾医药此前曾四次递交H股发行上市申请，期间曾在2021年6月通过港交所聆讯，但彼时公司未启动招股。今年上半年，亿腾医药收入同比有所下降。招股书称，原因主要有两方面：一是公司三款原研产品之一亿瑞平的收入减少；二是公司创新产品Mulpleta的收入减少。编辑｜益达来源｜综合整理于网络","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589222238","isCrawlerRequest":true}